ALLO News and Press, Allogene Therapeutics Inc. From 08/04/21

Allogene Therapeutics, Inc. (ALLO) Q2 2021 Earnings Conference Call August 04, 2021, 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and CEO Rafael Amado - EVP, Research and Development and CMO Eric Schmidt - CFO Conference Call Parti...

Allogene Therapeutics (NASDAQ:ALLO): Q2 GAAP EPS of -$0.53 beats by $0.02. Revenue of $0.04M. The Company had $913.2M in cash, cash equivalents, and investments as of June 30, 2021. Allogene continues to expect FY GAAP Operating Expenses to be between $300 and $330M including estima...

CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgk...

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Elizabeth (Liz) Barre...

SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2021 ...

ALLO is one of the front runners in the development of allogeneic CAR T cell therapies, with an exciting pipeline of candidates. The share price is currently expensive and appears to ignore risks that clinical trials may not be successful. Valuation should be revisited in the futu...

Gainers: [[ASPU]] +6.9%. [[SDC]] +4.9%. [[XM]] +4.5%. [[AFIB]] +4.3%. [[NERV]] +4.0%.Losers: [[SNBR]] -10.2%. [[LUMO]] -9.3%. [[KRUS]] -8.3%. [[ALLO]] -5.0%. [[SYBX]] -4.8%. For further details see: ASPU, AFIB, SNBR and LUMO among after-hours movers

Phase I trials mean more usual for Cellectis. Cellectis is pursuing low-hanging fruit indications. New pipeline programs and their IP position offer upside on top of their CAR-T programs. For further details see: Cellectis Offers An Idiosyncratic Risk Profile With Remark...

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at $23.10, breaking its 52-week low. So far today approximately 254,000 shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares. Allogene Therapeutics Inc. share prices have moved between a ...

Allogene Therapeutics (ALLO) perks up 5% premarket after announcing that the FDA has granted Fast Track designation to ALLO-605, the next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma.Fast Track status provides for...